RICHMOND, Calif., March 28, 2012 /PRNewswire/ --Sangamo
BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO,
will provide an update on the progress of Sangamo's ZFP
Therapeutic® development programs and an overview of the company's
business strategy at 8:40 am ET on
Wednesday, April 4, 2012, at the 11th
Annual Needham Healthcare Conference which will be held in
New York City.
The presentation will be webcast live and may be accessed via a
link on the Sangamo BioSciences website in the Investor Relations
section http://investor.sangamo.com/index.cfm under Events and
Presentations. The presentation will be archived on the Sangamo
website for two weeks after the event.
About Sangamo
Sangamo BioSciences, Inc. is focused on research and
development of novel DNA-binding proteins for therapeutic gene
regulation and genome editing. It has ongoing Phase 2 and Phase 1/2
clinical trials to evaluate the safety and efficacy of a novel ZFP
Therapeutic® for the treatment of HIV/AIDS. Sangamo's other
therapeutic programs are focused on monogenic diseases, including
hemophilia and hemoglobinopathies such as sickle cell anemia
and beta-thalassemia, and a program in Parkinson's disease.
Sangamo's core competencies enable the engineering of a class of
DNA-binding proteins known as zinc finger DNA-binding proteins
(ZFPs). Engineering of ZFPs that recognize a specific DNA
sequence enables the creation of sequence-specific ZFP Nucleases
(ZFNs) for gene modification and ZFP transcription factors (ZFP
TFs) that can control gene expression and, consequently, cell
function. Sangamo has entered into a strategic collaboration
with Shire to develop therapeutics for hemophilia and other
monogenic diseases and has established strategic partnerships with
companies in non-therapeutic applications of its technology
including Dow AgroSciences and Sigma-Aldrich Corporation. For more
information about Sangamo, visit the company's website at
www.sangamo.com
ZFP Therapeutic® is a registered trademark of
Sangamo BioSciences, Inc.
SOURCE Sangamo BioSciences, Inc.